Gyma Recalls Clonidine Base Micronized Due to Manufacturing Deviations
Gyma Laboratories of America, Inc. is recalling Clonidine Base Micronized due to lack of good manufacturing practices identified by the Italian Medicines Agency.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II, which typically involves a temporary or medically reversible adverse health consequence. The source text cites cGMP deviations without reporting specific illnesses or injuries, fitting the criteria for a moderate severity precautionary recall.
Plain-English summary
Gyma Laboratories of America, Inc. is recalling Clonidine Base Micronized, 55.8 Kg, Rx Only, S.I.M.S., Chemical Product for Medicines Preparation, Made in Italy, NDC 12660-0503-01. The affected lot numbers are 166247 and 166248, with an expiration date of 10/2016. The product is distributed nationwide.
The recall was initiated after the company received a Rapid Alert Notification from the Italian Medicines Agency. The notification indicated that the Active Pharmaceutical Ingredients were manufactured in Italy with a lack of good manufacturing practices (cGMP deviations).
This recall involves a chemical product used for medicines preparation. Consumers and healthcare providers should check their inventory for the specific lot numbers and expiration dates listed above. If the product is found, it should be removed from use and returned to the supplier or disposed of according to local regulations.
The recalled product
- Product
- Clonidine Base Micronized, 55.8 Kg, Rx Only, S.I.M.S. , Chemical Product for Medicines Preparation, Made in Italy, NDC 12660-0503-01
- Manufacturer
- Gyma Laboratories Of Amer,Inc
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (3)
- Lot Numbers: 166247
- 166248
- Exp 10/2016
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Gyma Laboratories Of Amer,Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Gyma Laboratories Of Amer,Inc
See all →- ModerateGyma Laboratories Recalls Clonidine HCL Due to Manufacturing Deviations
FDA (Drugs) · 2014-10-22
- ModerateGyma Laboratories Recalls Propranolol HCl Due to Manufacturing Deviations
FDA (Drugs) · 2014-10-22
- ModerateGyma Recalls Dipyridamole API Due to Manufacturing Deviations
FDA (Drugs) · 2014-10-22
Same hazard · cGMP deviation
See all →- HighCinacalcet Tablets Recalled for N-Nitroso Impurity Exceeding Limits
FDA (Drugs) · 2026-07-08
- SevereCinacalcet Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-08
- ModerateFentanyl Citrate Injectable Solution Recalled for cGMP Deviations
FDA (Drugs) · 2026-05-06
- ModerateIndomethacin Extended-Release Capsules recalled for cGMP deviations
FDA (Drugs) · 2025-06-11
- SevereLubricant Eye Drops Solution recalled due to sterility assurance concerns
FDA (Drugs) · 2025-05-14
Similar recalls
- ModerateClonidine HCl USP Recalled Due to Missing Stability Data
FDA (Drugs) · 2018-02-28
- ModeratePD-Rx Recalls Clonidine Hydrochloride Tablets Due to cGMP Deviations
FDA (Drugs) · 2016-01-06
- ModerateMutual Pharmaceutical Recalls Clonidine Hydrochloride Tablets Due to cGMP Deviations
FDA (Drugs) · 2015-08-05
- ModerateClomiphene Citrate USP Active Pharmaceutical Ingredient Recalled for cGMP Deviations
FDA (Drugs) · 2026-07-15
- ModerateX-Gen Recalls Clonidine Injection Vials Due to Labeling Error
FDA (Drugs) · 2019-04-17
- LowX-Gen Recalls Clonidine HCl Injection Due to Labeling Error
FDA (Drugs) · 2014-07-30